Trial intelligence / Profile preview

Phase 2 Open-Label Study of Surufatinib in Neuroendocrine Tumours in Europe

2020-006118-19Phase 2Completed

Sponsor

Hutchison MediPharma (HMP)

Start

Mar 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1